MidWestOne Financial Group’s Soleno Therapeutics SLNO Stock Holding History

MidWestOne Financial Group’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.01M	Buy	+21,817	New	+$1.2M	0.11%	163

Other funds holding SLNO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MidWestOne Financial Group's SLNO Position: Q4 2025 in Review

MidWestOne Financial Group opened a new position in Soleno Therapeutics (SLNO) in Q4 2025: 21,817 shares worth $1.01M. The stake represents 0.11% of the portfolio and ranks #163 among its holdings.

248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

MidWestOne Financial Group held 21,817 shares of Soleno Therapeutics worth $1.01M as of Q4 2025.
Soleno Therapeutics was a new MidWestOne Financial Group position in Q4 2025.
Soleno Therapeutics made up 0.11% of MidWestOne Financial Group's portfolio in Q4 2025, its #163 holding.
248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on MidWestOne Financial Group's 13F filing for Q4 2025, filed 12 Feb 2026.